Share Name Share Symbol Market Type Share ISIN Share Description
Instem LSE:INS London Ordinary Share GB00B3TQCK30 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 160.00p 155.00p 165.00p 161.00p 160.00p 161.00p 1,500 16:08:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 18.3 0.0 6.9 23.2 25.24

Instem Share Discussion Threads

Showing 876 to 898 of 900 messages
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
DateSubjectAuthorDiscuss
16/5/2017
08:42
Clinical was the drag, x-Clinical was positive. Progressive Research (not independent) made the interesting observation below in their most recent analysis. Find out soon if true. If it does come about then INS should see some response in future results. "It is also worth noting that growth in the global volume of pre-clinical studies was depressed during the period 2010-13. Hindsight shows this to have been a LEAD INDICATOR of softness in Clinical during 2016. Citeline data shows GROWTH in pre-Clinical RETURNED in 2014 and has been SUBSEQUENTLY ROBUST. To us this SUGGESTS the outlook for Clinical will be supported by a MORE FAVOURABLE industry BACKDROP over the near term."
p1nkfish
01/5/2017
23:19
Possibly. If get chance. Travel a lot, in out of UK until 3rd week Dec.
p1nkfish
29/4/2017
17:23
Thanks p1nkfish - Maybe you should?
brummy_git
29/4/2017
17:02
Never met them Brummy.
p1nkfish
29/4/2017
07:49
p1nkfish - Have you ever met the CEO and FD? If so, what do you think of them?
brummy_git
28/4/2017
23:01
I do enjoy a quiet pbb, especially when a large investor repeatedly ups their holding in an otherwise unloved company with small float.
p1nkfish
26/4/2017
09:46
RNS to confirm revenue and profit for below from March 28th results will be recognised in the current FY. Now we know! "We are pleased to report that the order expanding the utilisation of Provantis at the US National Institute of Environmental Health Sciences ("NIEHS"), delayed from 2016, has recently been received and the appropriate accounting treatment for revenue and profit recognition purposes is currently being assessed."
p1nkfish
17/4/2017
17:40
Where the US goes, we go. Healthcare one of the few sectors showing some potential upside vs downside. Http://www.zerohedge.com/sites/default/files/images/user5/imageroot/2017/04/15/overvalued%20bofa%202.jpg
p1nkfish
04/2/2017
23:28
So much for the share event. At least approaching buy zone again.
p1nkfish
19/1/2017
15:08
Promotional post - The Growth and Innovation Forum will show you how to take advantage of new investment opportunities in technology stocks and funds. Come and see Terry Hart, CFO – CityFibre and 20 other companies present at the Growth and Innovation Forum on 31st January 2017 at Business Design Centre London. Find the next stock market ‘winner’. Satellite Solutions Worldwide +79%, CyanConnode +43%, Instem + 44%, Summit Therapeutics +32% and XLMedia +46% all attended last year. Click to register to attend for free Https://goo.gl/J9pCpW The other companies also presenting Jaywing, RedstoneConnect, Blancco Technology Group, CloudCall, Frontier IP Group, CyanConnode, Bango, LoopUp, CityFibre, TP Group, AJ Bell, ANGLE, Legal & General UK Alpha Trust, Defenx, Instem, WANdisco, Collagen Solutions, Avacta, One pm Finance, Cenkos Securities and Mirada. Https://goo.gl/J9pCpW
sharesevents
16/1/2017
10:04
I think run to 260p possible in short order.
p1nkfish
16/1/2017
10:03
Nothing to be concerned about on the update and the delayed orders to £1.2M should land 2017. Net cash increase of £1.9M "Importantly, the overall market dynamics for our products and services remains positive and we therefore look forward to the next financial year with increasing optimism." Increasing optimism - interesting.
p1nkfish
21/12/2016
20:50
Logos man sold out. Any price sub £2 is a bargain.
p1nkfish
15/12/2016
22:26
Look on the bright side, £700k less paid out but better if the acquisition had performed.
p1nkfish
21/11/2016
12:03
I'm still in the money on INS but have also decided to add a fair few. I also see this as not a showstopper, just a trip on the way to the stage.
p1nkfish
21/11/2016
07:42
Looking at the price graph above who said info doesn't leak if that price move is from last Friday (I didn't check)? Hold - these are delays and the foundations are still sound and the 2017 looking to have not been harmed.
p1nkfish
29/10/2016
02:06
Sbs went private. Crx likely to be acquired. Who next?
p1nkfish
06/9/2016
17:19
Pleasing to see this rise. Not many of us here so all the best whoever is on the same raft.I hold crx, held sbs, hold odx. A useful UK biotechnology grouping with ins.
p1nkfish
25/8/2016
11:56
Video interview with Phil Reason https://www.youtube.com/watch?v=Cbdhe_Yx6CY Instem PLC (LON:INS) chief executive Phil Reason tells Proactive Investors that the company wants to “dominate” niche markets after it announced a solid first six months of trading in 2016. “We think we can do as we do in many other areas of our business and be a market leader in a particular niche,” Reason says. “We have some particular areas where we think we can dominate some of those niches.” Reason adds that the biotech industry, the company’s main market, has been “buoyant” for the last couple of years and he expects it to remain that way for the foreseeable future. “The contact research organisations that make up a lot of our client base today, their facilities are generally full as they conduct probably the largest numbers of studies they’ve ever enjoyed.”
proactivest
16/8/2016
11:55
Yup. One of my larger holdings.
wjccghcc
16/8/2016
11:50
Anyone else here. As bio turns round I expect this to move up a gear. Steady as she goes in the meantime.
p1nkfish
31/5/2016
23:02
Sensible looking acquisition.
p1nkfish
05/4/2016
15:40
Video interview with Nigel Goldsmith http://tinyurl.com/zgkchvb Nigel Goldsmith, chief financial officer of Instem PLC (LON:INS) tells Proactive the firm had an “exceptionally good year in 2015”, which has given it a “very strong platform” for this year. The company, which develops software used in clinical trials, recorded significant year-on-year growth in 2015 as its main markets continue to expand. Revenues increased by 22% in the 12 months to December 31 to £16.3mln, £10mln of which were recurring. Instem also increased its cash reserves, and Goldsmith says this, combined with a £5mln fundraise, will allow the company to look at “new acquisitions” in a “fragmented sector” with “lots of opportunities”.
proactivest
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170823 17:50:04